The apelin-APJ system in the evolution of heart failure

Authors

DOI:

https://doi.org/10.15386/cjmed-380

Keywords:

apelin, APJ receptor, heart failure, biomarker

Abstract

Heart failure is a chronic, progressive disease in which the overexpression of biologically active molecules and neurohomonal activation are the key factors of the evolution and natural history. The apelin-APJ system is a newly discovered molecular pathway and the RAAS counterbalance is its principal effect. The apelin is a potent inotrope, vasodilator and diuretic with crucial cardioprotective effects against angiotensin and aldosterone injuries. Intense and prolonged RAAS induces the downregulation of the apelin and its receptor at myocardial level and cancels their protection. Compared to the vasoactive agents used in the treatment of acute heart failure, exogen apelin has unique intropic and vasodilatory effects without deleterious consequences, being a promising therapeutic option.

Author Biographies

Cerasela Mihaela Goidescu, University of Medicine and Pharmacy „Iuliu Hațieganu”

1st Medical Clinic, Department of Internal Medicine, Cardiology and Gastroenterology, Cluj-Napoca

Luminița Animarie Vida-Simiti, University of Medicine and Pharmacy „Iuliu Hațieganu”

1st Medical Clinic, Department of Internal Medicine, Cardiology and Gastroenterology, Cluj-Napoca

Downloads

Additional Files

Published

2015-01-28

How to Cite

1.
Goidescu CM, Vida-Simiti LA. The apelin-APJ system in the evolution of heart failure. Med Pharm Rep [Internet]. 2015 Jan. 28 [cited 2025 Oct. 6];88(1):3-8. Available from: https://medpharmareports.com/index.php/mpr/article/view/380

Issue

Vol. 88 No. 1 (2015)

Section

Reviews

License

The authors are required to transfer the copyright of the published paper to the journal. This is done by agreeing to sign the Copyright Assignment Form. Whenever the case, authors are also required to send permissions to reproduce material (such as illustrations) from the copyright holder.

 Creative Commons License
The papers published in the journal are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.